

Registration number 07600364

Frontline Pharma Consulting Limited
Director's report and unaudited financial statements
for the year ended 31 May 2013

WEDNESDAY



A2ZM9808

A30

15/01/2014

#218

COMPANIES HOUSE

Frontline Pharma Consulting Limited

Company information

Director	S. Eisen
Company number	07600364
Registered office	Bigbear House Saddlers Close Arkley Herts EN5 3LU
Accountants	Ramsay Brown and Partners Ramsay House 18 Vera Avenue Grange Park London N21 1RA
Client reference	F282

Frontline Pharma Consulting Limited

Contents

	Page
Director's report	1
Accountants' report	2
Profit and loss account	3
Balance sheet	4 - 5
Notes to the financial statements	6 - 8

Fronline Pharma Consulting Limited

**Director's report
for the year ended 31 May 2013**

The director presents his report and the financial statements for the year ended 31 May 2013

Principal activity

The principal activity of the company is that of providing medical, pharmaceutical and regulatory consulting services.

Director

The director who served during the year is as stated below:

S. Eisen

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on ... *18th Dec 2013* and signed on its behalf by



.....
S. Eisen
Director

Frontline Pharma Consulting Limited

**Chartered Accountants' report to the Director on the
unaudited financial statements of Frontline Pharma Consulting Limited**

In order to assist you to fulfil your duties under the Companies Act 2006, we have compiled the financial statements of the company which comprise the Profit and Loss Account, the Balance Sheet and the related notes from the accounting records and information and explanations you have given to us

Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's director that we have done so and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's director for our work or for this report.

We have carried out this engagement in accordance with technical guidance issued by the Institute of Chartered Accountants in England & Wales and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the balance sheet for the year ended 31 May 2013 your duty to ensure that the company has kept proper accounting records and to prepare financial statements that give a true and fair view under the Companies Act 2006. You consider that the company is exempt from the statutory requirement for an audit for the year.

We have not been instructed to carry out an audit of the financial statements. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.



.....
Ramsay Brown and Partners
Chartered Accountants

Ramsay House
18 Vera Avenue
Grange Park
London
N21 1RA

Date.....
18/12/13

Frontline Pharma Consulting Limited

**Profit and loss account
for the year ended 31 May 2013**

		Year ended 31/05/13	Period ended 31/05/12
	Notes	£	£
Turnover	2	215,436	206,487
Administrative expenses		<u>(62,549)</u>	<u>(23,670)</u>
Operating profit	3	152,887	182,817
Other interest receivable and similar income		<u>2,208</u>	<u>-</u>
Profit on ordinary activities before taxation		155,095	182,817
Tax on profit on ordinary activities	4	<u>(30,646)</u>	<u>(35,992)</u>
Profit for the year		124,449	146,825
Retained profit brought forward		146,825	-
Reserve Movements		<u>(33,158)</u>	<u>-</u>
Retained profit carried forward		<u><u>238,116</u></u>	<u><u>146,825</u></u>

The notes on pages 6 to 8 form an integral part of these financial statements.

Frontline Pharma Consulting Limited

**Balance sheet
as at 31 May 2013**

		31/05/13		31/05/12	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	6		5,179		3,314
Current assets					
Debtors	7	20,310		11,505	
Cash at bank and in hand		260,845		198,826	
		<u>281,155</u>		<u>210,331</u>	
Creditors: amounts falling due within one year	8	<u>(48,118)</u>		<u>(66,720)</u>	
Net current assets			<u>233,037</u>		<u>143,611</u>
Total assets less current liabilities			238,216		146,925
Net assets			<u><u>238,216</u></u>		<u><u>146,925</u></u>
Capital and reserves					
Called up share capital	9		100		100
Profit and loss account			<u>238,116</u>		<u>146,825</u>
Shareholders' funds			<u><u>238,216</u></u>		<u><u>146,925</u></u>

The director's statements required by Sections 475(2) and (3) are shown on the following page which forms part of this Balance Sheet

The notes on pages 6 to 8 form an integral part of these financial statements.

Frontline Pharma Consulting Limited

Balance sheet (continued)

**Director's statements required by Sections 475(2) and (3)
for the year ended 31 May 2013**

In approving these financial statements as director of the company I hereby confirm

- (a) that for the year stated above the company was entitled to the exemption conferred by Section 477 of the Companies Act 2006 ;
- (b) that no notice has been deposited at the registered office of the company pursuant to Section 476 requesting that an audit be conducted for the year ended 31 May 2013 ; and
- (c) that I acknowledge my responsibilities for:
 - (1) ensuring that the company keeps accounting records which comply with Section 386 , and
 - (2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Section 393 and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements were approved by the Board on 16th Dec 2013 and signed on its behalf by



**S. Eisen
Director**

Registration number 07600364

The notes on pages 6 to 8 form an integral part of these financial statements.

Frontline Pharma Consulting Limited

Notes to the financial statements for the year ended 31 May 2013

1. Accounting policies

1.1. Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

1.2. Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year and derives from the provision of goods falling within the company's ordinary activities.

1.3. Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows.

Computer equipment - 25% straight line

2. Turnover

Turnover attributable to geographical markets outside the United Kingdom amounted to 42% for the year

3. Operating profit

Operating profit is stated after charging:

Depreciation and other amounts written off tangible assets

Year ended	Period ended
31/05/13	31/05/12
£	£
2,094	1,104

4. Tax on profit on ordinary activities

Analysis of charge in period

Current tax

UK corporation tax at 20.00% (2012 - 20.00%)

Year ended	Period ended
31/05/13	31/05/12
£	£
30,646	35,992

Frontline Pharma Consulting Limited

**Notes to the financial statements
for the year ended 31 May 2013**

..... continued

5. Dividends

Dividends paid and proposed on equity shares

	Year ended 31/05/13 £	Period ended 31/05/12 £
Paid during the year		
Equity dividends on Ordinary shares	33,158	-
	33,158	-

6. Tangible fixed assets

	Computer equipment £	Total £
Cost		
At 1 June 2012	4,418	4,418
Additions	3,959	3,959
At 31 May 2013	8,377	8,377
Depreciation		
At 1 June 2012	1,104	1,104
Charge for the year	2,094	2,094
At 31 May 2013	3,198	3,198
Net book values		
At 31 May 2013	5,179	5,179
At 31 May 2012	3,314	3,314

7. Debtors

	31/05/13 £	31/05/12 £
Trade debtors	20,210	11,405
Called up share capital not paid	100	100
	20,310	11,505

Frontline Pharma Consulting Limited

**Notes to the financial statements
for the year ended 31 May 2013**

... .. continued

8. Creditors: amounts falling due within one year	31/05/13	31/05/12
	£	£
Corporation tax	30,646	35,992
Other taxes and social security costs	16,248	7,686
Director's accounts	-	21,842
Accruals and deferred income	1,224	1,200
	<u>48,118</u>	<u>66,720</u>
9. Share capital	31/05/13	31/05/12
	£	£
Allotted, called up and fully paid		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>
Equity Shares		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>

10. Controlling interest

The company was controlled throughout the current accounting period by its director Dr S. Eisen, who is also the sole shareholder.